natgillin/translations-raw huggingface dataset:
FIGS. 4 to 6 show schematic partial sections of the discharge device with the metered dose valve 2 according to a first embodiment of the present invention. 
Slike 4 do 6 prikazuju shematski djelomične presjeke naprave za pražnjenje 1 s ventilom za odmjeravanje doze 2 prema prvoj izvedbi predloženog izuma.
The kit according to claim 14 further comprising instructions for use of the compound in the treatment of cancer, and more preferably a cancer selected from lung cancer, including non-small cell lung cancer and small cell lung cancer, colon cancer, colorectal cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer and gastric cancer. 
Komplet u skladu sa patentnim zahtjevom 14 koji dalje sadrži uputstva za primjenu sjedinjenja u liječenju raka, i poželjnije raka odabranog od raka pluća, uključujući rak pluća nemalih stanica i rak pluća malih stanica, raka debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika i raka želuca.
a VH region as depicted in SEQ ID NO: 7, and a VL region as depicted in SEQ ID NO: 8; 
VH regiju kao što je prikazano u SEQ ID NO: 7, i VL regiju kao što je prikazano u SEQ ID NO: 8;
Device according to any of the claims 1-11, wherein, in the working configuration, the base plane (X) defines an angle (A) with a horizontal plane (S) comprised in a range 1-16°. 
Uređaj prema bilo kojem od zahtjeva 1-11, pri čemu, u radnoj konfiguraciji osnovna ravnina (X) s horizontalnom ravninom ($S) definira kut (A), koji se nalazi u granicama od 1-16".
wherein said antigen binding protein or said antibody is an antibody fragment wherein said antibody fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule; or 
je podtipa IgG1, IgG2, IgG3 ili IgG4; je ljudsko protutijelo podtipa IgG1, IgG2, IgG3 ili IgG4; je Fab fragment, Fab’ fragment, F(ab’)2 fragment, Fv fragment, dijatijelo, domensko protutijelo, ili jednolančana molekula protutijela; ili
The slurry is heated to 40 °C and aged 1 h at 40°C and then cooled to 25 °C over 2 h. 
(c) Smjesa se zagrijava do 40"C i ostavlja 1 h na 40"C, a zatim hladi do 25"C tijekom 2 h.
In this way the edges of the wall elements 2 have a stepped configuration of which middle step has a height preferably corresponding to the thickness of the columns 1, while the depth of the first and last step preferably corresponds to half the width of the projected columns 1. 
Na taj način bridovi zidnih elemenata 2 imaju stepenasti oblik od kojih srednja stepenica po mogućnosti odgovara debljini stupova 1, dok dubina prve i zadnje stepenice po mogućnosti odgovara polovici širine pripadnog stupa 1.
A gene vector for use in gene therapy for transduction or transfection of hematopoietic stem or progenitor cells, the gene vector comprising at least one mir-130a and/or mir-126 target sequence operably linked to a nucleotide sequence encoding a transgene selected from an immunomodulatory molecule, lysosomal enzyme galactocerebrosidase, and gp91 phox, such that: 
Genski vektor za uporabu u genskoj terapiji koji sadrži najmanje jednu miRNA ciljanu sekvencu koja odgovara mir-130a ili mir-126 operativno povezanoj s transgenom koji kodira interferon-alfa, lizosomalni enzim galaktocerebrozidaze ili gp91 phox, naznačen time što se genski vektor koristi za sprječavanje ili smanjenje ekspresije transgena u krvotvornoj matičnoj stanici ili krvotvornoj progenitornoj stanici.
Cancer Res., 2001, 7, 1850) as well as other cancers of the lung (Hendler et al., Cancer Cells, 1989, 7, 347; Ohsaki et al., Oncol. 
Cancer Res., 2001, 7, 1850) kao i ostalim plućnim tumorima (Hendler i sur., Cancer Cells, 1989, 7, 347; Ohsaki i sur., Oncol.
1 shows the general structure of the oil well. 
Slika 1 prikazuje općenitu strukturu naftnog izvora.
A composition according to claim 14 or 15, comprising 30 to 70 % by weight of granisetron (expressed as the free base). 
Kompozicija prema zahtjevu 14ili 15, koja sadrži 30 do 70% težinskih granisetrona (izraženog kao slobodna baza).
The compound according to claim 1 which is (R)-4-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-3-(3-phosphonopropanamido)butanoic acid o r a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time, da je to (R)-4-(5'-kloro-2'-fluoro-[L,1'-bifenil]-4-il)-3- (3-fosfono propanamido)butanska kiselina ili njegova farmaceutski prihvatljiva sol.
The method of claim 3, wherein the coefficient a is about 0.33. 
Metoda zahtjeva 1 do 7, pri čemu je gdje je a težinski faktor oko 0.33.
Therefore, this arrangement can be used to effect orthogonal flow through the microfluidic arrangement 1 as seen from the outside, in contrast to the lateral flow in the example according to the first embodiment which was described above. 
Zbog toga se tu napravu može upotrijebiti za provedbu okomitog protoka kroz mikrofluidnu napravu 1, kako se vidi izvana, suprotno bočnom protoku u primjeru prema prvoj izvedbi koja je bila gore opisana.
The closure for a vial or a plunger for a hypodermic syringe of claim 1 wherein the colourant comprises a pigment or mixture of pigments mixed with a carrier material. 
Zatvarač za bočicu ili klip za potkožnu špricu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, što sredstvo za bojenje sadržava pigment ili mješavinu pigmenata koji su pomiješani s materijalom nosiocem.
GnRH is diluted in 0.1% BSA containing FLIPR buffer (Hanks balanced salt, 20 mM HEPES) to a concentration of 20 nM and dispensed into a 96-well plate (Low protein binding). 
GnRH je Tazrijeđen u 0,1 % BSA koji sadrži FLIPR pufer (Hanksova uravnotežena sol, 20 mM HEPES) do koncentracije od 20 nM, te razdijeljen na ploči s 96 jažica (Nisko vezanje proteina).
The chimeric polypeptide of claim 1-2, wherein the active conformation is an agonist conformation, a partial agonist conformation, or a biased agonist conformation. 
Himerni polipeptid u skladu s patentnim zahtjevom 1 do 2, naznačen time, da je aktivna konformacija konformacija agonista, konformacija djelomičnog agonista ili konformacija agonista s odstupanjem.
A salt according to any one of claims 1 to 11, a pharmaceutical composition according to claim 12 or a combination according to claim 13 for use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of dihydroorotate dehydrogenase, wherein the pathological condition or disease is preferably selected from rheumatoid arthritis, psoriatic arthritis, ankylosing spondilytis, multiple sclerosis, Wegener's granulomatosis, systemic lupus erythematosus, psoriasis and sarcoidosis. 
Sol prema bilo kojem zahtjevu od 1 do 11, farmaceutska kompozicija prema zahtjevu 12 ili kombinacija prema zahtjevu 13 za uporabu u liječenju patoloških stanja ili bolesti koje se mogu poboljšati inhibicijom dihidroorotat dehidrogenaze, naznačena time, što je poželjno da se patološka stanja ili bolesti odnose na reumatoidni artritis, psorijazni artritis, ankilozantni spondilitis, multiplu sklerozu, Wegenerovu granulomatozu, sustavni eritemski lupus, psorijazu i sarkoidozu.
Step 3: adjustment of the free species 
Datum objave europskog patenta:
The method of claim 1 wherein: the drain water is urged to flow in a first direction and the fresh water is urged to flow in a second direction; and 
Postupak prema zahtjevu 1 gdje: drenažna voda protječe u prvom smjeru i svježa voda protječe u drugom smjeru; i prvi smjer je u biti jednak drugom smjeru.
The method according to claim 2 wherein the recombinant microorganism is Escherichia coli DSM23644 or Escherichia coli DSM23578. 
Postupak biotehnološke proizvodnje hondroitina u skladu s patentnim zahtjevom 12, naznačen time što je rekombinantni mikroorganizam Escherichia coli DSM23578 ili Escherichia coli DSM23644.
A system according to claim 46 comprising a capsule according to claim 1, wherein the further ridge is arranged to abut against an outer circumferential surface of the enclosing member. 
Sistem prema patentnom zahtjevu 19 obuhvaća kapsulu (110) prema patentnom zahtjevu 11, pri čemu je još jedan ispust (40) raspoređen da se nasloni na vanjsku obodnu površinu obuhvatnog elementa (108).
The formulation according to claim 1, wherein compound of formula (I) or its co-crystal is present in amount from 0.1% to 80% w/w of total formulation, preferably in an amount from 0.25% to 70% w/w of total formulation, most preferably in an amount of 5% to 50% w/w of total formulation. 
Formulacija sukladno patentnom zahtjevu 1, pri čemu su jedinjenje formule (I) ili njegov kokristal prisutni u količini od 0,1 do 80 težinskih postotaka ukupne formulacije, poželjno u količini od 0,25 do 70 težinskih postotaka ukupne formulacije, najpoželjnije u količini od 5 do 50 težinskih postotaka ukupne formulacije.
A method for loading catalyst using a pneumatic device for densely filling catalyst into a steam reforming exchanger-reactor consisting of a plurality of bayonet tubes enclosed in a shell, the catalyst being constituted by particles occupying at least part of the annular space (4) included between an internal tube (5) and an external tube (6), the assembly of these two tubes constituting a bayonet tube, the width of said annular space being in the range 30 mm to 80 mm, and its height being in the range 10 to 20 meters, the catalyst particles being in the form of cylinders with an approximate height of 10 mm to 20 mm and with an approximate diameter of 5 mm to 20 mm, the device consisting of: 
Postupak za punjenje čestica katalizatora u parni reaktor-izmjenjivač za reformiranje koji se sastoji od mnoštva bajunetnih cijevi zatvorenih u ljusci, pri čemu katalizator sadrži čestice koje zauzimaju barem dio prstenastog prostora (4) koji se nalazi između unutarnje cijevi (5) i vanjske cijevi (6), te sklop tih dviju cijevi čini bajonetnu cijev, širina navedenog prstenastog prostora je u rasponu od 30 mm do 80 mm, a njegova visina je u rasponu od 10 do 20 metara, navedene čestice katalizatora su u obliku cilindara približne visine od 10 mm do 20 mm i približnog promjera od 5 mm do 20 mm, navedeni postupak punjenja koristi uređaj za zbijeno punjenje katalizatora koji se sastoji od:
The following modifications are used as shown in reaction scheme below: toluene is used in Step 3 and Method 2 (Example 3, Step 4) is used in Step 4 with 1,1'-carbonyldiimidazole in ethyl acetate. 
Upotebljava se sljedeće modifikacije, kao što je prikazano u reakcijskoj shemi, niže: toluen se upotrebljava u Koraku 3 i Postupku 2 (Primjer 3, Korak 4), te u Koraku 4 uz 1,1'-karbonildiimidazol u etil-acetatu.
The material was filtered and dried at 55-60° C. to obtain 28.0 g of the title compound. 
Materijal je profiltriran 1 osušen na 55-60 "C da bi se dobilo 28,0 g spoja iz naslova.
The BOG, which is compressed by the compressor and is transferred to the heat exchanger, may be compressed while passing through all or part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što otpareni plin poslan u izmjenjivač topline (21) je otpareni plin komprimiran prilikom prolaska kroz sve ili dio kompresijskih elemenata koje sadrži kompresor (13,13,13b).
iii) in both Fab fragments of a) the variable domains VL and VH are replaced by each other, or the constant domains CL and CH1 are replaced by each other, and in both Fab fragments of b) the variable domains VL and VH are replaced by each other, and the constant domains CL and CH1 are replaced by each other, 
međusobno se zamjenjuju varijabilne domene VL i VH ili se međusobno zamjenjuju konstantne domene CL i CH1 u oba Fab-fragmenta iz točke (a) te se međusobno zamjenjuju varijabilne domene VL i VH i međusobno se zamjenjuju konstantne domene CL i CH1 u oba Fab-fragmenta iz točke (b);
High number of Nosema apis spores 
Broj međunarodne objave:
The method as claimed in one of claims 8-10, comprising the steps of using strips of flexible material which comprise a fabric, and of aligning the threads in the longitudinal direction of the core elements. 
Postupak u skladu s jednim od patentnih zahtjeva 8 do 10, naznačen time što sadržava korake upotrebe trake od fleksibilnog materijala, koji materijal sadržava proizvod od tekstila odnosno tkani proizvod 1 vlakna koja su postavljena u smjeru koji je uzdužan sa središnjim elementima,
A compound of Formula Ic' 
Spoj Formule Ic’ [image]
Another aspect of the invention is a method for treating HIV infection in a patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, with a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection. 
Pored toga, izum se odnosi na spojeve prema izumu za primjenu u postupku liječenja HTV infekcije kod pacijenta koji uključuje primjenu terapijski učinkovite količine spoja formule I, ili njegove farmaceutski prihvatljive soli ili solvata, sa terapijski učinkovitom količinom najmanje jednog drugog sredstva koje se koristi za liječenje SIDA-e ii HIV-a.
and R5 independently of one another being selected from the group of H-, fluorine, and methyl; x is 0, 1, 2, 3 or 4; 
R*i R? su međusobno neovisno odabrani iz skupine koju čine: H-, fluor i metil; xje0,1,2,3ili 4; yje0il 1; ili njegove farmaceutski prihvatljive soli.
Such derivatives are formed by reacting compounds of formula I with alkylating-, acylating-, sulfonylating-, or phosphorylating reagents employing procedures known to those skilled in the art. 
Takvi derivati se formiraj u reakcijom spojeva formule I sa alkilirajućim-, acilirajućim-, sulfonirajućim-, fosforilirajućim reagensima primjenom postupaka koji su poznati osobama iz struke.
In another embodiment of the invention, the inhalable form is a dry powder, i.e. 
U drugoj izvedbi izuma, oblik koji se može inhalirati je suhi prah, tj.
The reaction was stirred at room temperature for 45 minutes then was worked up by extracting the product with EtOAc and washing with saturated sodium bicarbonate solution followed by water. 
Reakcijska smjesa je bila miješana na sobnoj temperaturi 45 minuta i tada je bila dorađena ekstrahiranjem produkta s EtOAc i ispiranjem sa zasićenom otopinom natrij bikarbonata i nakon toga s vodom.
The culture medium in the preceding step contains—analogously to or independently of the composition of the medium in the secretion step—nitrate ions, preferably in a concentration of at least 0.2 mM, phosphate ions, preferably in a concentration of at least 0.05 mM, sulfate ions, preferably in a concentration of at least 0.02 mM, calcium ions, preferably in a concentration of at least 0.1 mM, potassium ions, preferably in a concentration of at least 0.1 mM, or combinations thereof, thereby facilitating optimal cell growth. The maximal concentration of the sodium ions is 20 mM, particularly preferably 15 mM or 10 mM. 
Postupak prema patentnom zahtjevu 8, naznačen time što kultivacijski medij, u navedenom prethodnom koraku, sadrži nitratne ione, poželjno u koncentraciji od najmanje 0,2 mM, fosfatne ione, poželjno u koncentraciji od najmanje 0,05 mM, sulfatne ione, poželjno u koncentraciji od najmanje 0,02 mM,, kalcijeve ione, poželjno u koncentraciji od najmanje 0,1 _mM, kalijeve ione, poželjno u koncentraciji od najmanje 0,1 mM, ili njihove kombinacije; i/ili sadrži natrijeve ione u koncentraciji od najviše 20 mM.
An image processing apparatus for processing an image obtained by fluoroscopying a subject, the image processing apparatus includes: a band-image generating device (12) configured to generate a band image by extracting a part of frequency components in an original image (P0) with a figure of the subject appearing therein; 
(A) uređaj za stvaranje slike na traci (12) koji ima konfiguraciju za stvaranje slike na traci pomoću ekstrakcije dijela frekvencijskih komponenti u originalnoj slici (PO) s likom pojedinca koji se pojavljuje na toj slici;
In some preferred embodiments, the dose of the antagonist is gradually reduced during a second treatment period that begins upon the end of the first treatment period, and typically has a duration of between one and three months. 
Antagonist za uporabu u skladu sa zahtjevom 45, naznačen time, da se doza antagonista postupno smanjuje za vrijeme drugog razdoblja liječenja koje započinje završetkom prvog razdoblja liječenja.
at least one second transformer arrangement with a primary side connectable to a second AC network (550b; 650b; 750b; 850b; 950b) and with a secondary side, at least one second converter unit (540b; 640b; 740c,d; 840c,d; 940c) connected to the secondary side of the second transformer arrangement, wherein the first and second converter units are interconnected by means of a DC connection (560, 562; 660, 662; 760, 762, 764; 860, 862; 960, 962), characterized in that at least part of two transformer arrangements are integrated in one transformer unit (530a-c; 630a-f; 730a-f; 830a-f; 930a-f). 
najmanje jedan drugi sklop transformatora s primarnom stranom koja se može spojiti na drugu AC mrežu (550b; 650b; 750b; 850b; 950b) 1 sa sekundarnom stranom, - < najmanje jednu drugu pretvaračku jedinicu (540b; 640b; 740c,d; 840c,d; 940c) spojenu na sekundarnu stranu sklopa drugog transformatora, pri čemu su prva i druga pretvaračka jedinica međusobno spojene pomoću DC spoja (560, 562; 660, 662; 760, 762, 764; 860, 862; 960, 962), naznačen time što su barem dijelovi i prvog i drugog sklopa transformatora integrirani u jednu fizičku transformatorsku jedinicu (530a-c; 630a-f; 730a-f; 830a-f; 930a-f), unutar zajedničkog kućišta transformatora, pri čemu su unutar kućišta transformatora predviđene dvije odvojene jezgre transformatora.
The use of claim 13, wherein the chronic demyelinating condition is multiple sclerosis, a chronic demyelinating neuropathy, HMSN (CMT) disease type IA and IB, Alzheimer's disease, Huntington's disease, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis (ALS), Guillain-Barre syndrome (GBS, also known as acute inflammatory demyelinating polyneuropathy or AIDP), leukodystrophy, or Parkinson's disease. 
Uporaba prema zahtjevu 13, naznačena time da je kronično demijelinizirajuće stanje multipla skleroza, kronična demijelinacijska neuropatija HMSN (CMT) tipa bolesti IA i IB, Alzheimerova bolest, Huntingtonova bolest, Charcot-Marie-Tooth bolest, amiotrofna lateralna skleroza (ALS), Guillain-Barre sindrom (GBS, također poznat kao akutna upalna demijelinacijska polineuropatija ili AIDP), leukodistrofija, ili Parkinsonova bolest.
In another embodiment, the antibody comprises an HCVR having an amino acid sequence selected from SEQ ID NO:360 and 376 with 4 or fewer conservative amino acid substitutions. 
360 i (b) CDR-ove lakog lanca (LCDRI, LCDR2 i LCDR3) iz varijabilne regije lakog lanca koja sadržava sekvencu aminokiselina koja se sastoji od SEQ ID NO: 365.
A method according to claim 1, wherein the method is performed at a mineral wool production line, which feeds a primary or secondary mineral wool web into the fiber disentanglement process. 
Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, pri čemu se taj postupak izvodi na liniji za proizvodnju mineralne vune, koja dovodi primarnu ili sekundarnu mrežu mineralne vune u postupak rasplitanja vlakna.
The system of claim 2, wherein the controlling server is further configured to generate said once-off shared keycode, and render it available at the accepting appliance. 
Sustav u skladu s patentnim zahtjevom 2, naznačen time što je kontrolni server (101) dodatno konfiguriran za generiranje navedenog jedinstvenog zajedničkog kodnog ključa, te ga čini dostupnim na prijemnoj napravi (109).
or a pharmaceutically acceptable salt, solvate, or prodrug thereof Item 38. The compound of item 37, wherein A1 is selected from the group consisting of substituted phenyl having one or two substituents and substituted pyridyl having one substituent, wherein each substituent is independently selected from the group consisting of halo, cyano, hydroxy, amino, haloalkyl, alkoxy, haloalkoxy, and alkyl. 
Zje -NH-, ili njena farmaceutski prihvatljiva sol ili solvat, i gdje je još poželjnije A' odabran iz grupe koja se sastoji od supstituiranog fenila koji ima jednog ili dva supstituenata 1 supstituiranog piridila koji ima jednog supstituenta, pri čemu je svaki supstituent nezavisno odabran iz grupe koja se sastoji od halo, cijano, hidroksi, amino, haloalkila, alkoksi, haloalkoksi i alkila.
The optical device of claim 1 wherein each diffractive optical element comprises grooves and a grating vector in the plane of the grooves, having a direction that is normal to the grooves and a magnitude which is inversely related to the pitch of the grooves, wherein the input and output diffractive optical elements respectively have grating vectors with a substantially equal magnitude. 
Optički uređaj u skladu s patentnim zahtjevom 1, naznačen time što svaki difraktivni optički element (17; H0; H1; H2) ima žljebove i vektor rešetke u ravnini žljebova, sa smjerom okomitim u odnosu na žljebove i veličinom obrnuto proporcionalnom nagibu žljebova, gdje ulazni i izlazni difraktivni optički elementi odgovarajuće imaju vektore rešetke uglavnom jednakih veličina.
is -O- wherein a compound of formula XXV is reacted with a compound of formula XXVI to generate a compound of formula XXVII in which formulae 
je -O-, naznačen time što spoj formule XXV [image] reagira sa spojem formule XXVI [image] kako bi se dobilo spoj formule XXVII [image], gdje formule
expanding the isolated DPFs in monolayer culture without collagen coating, wherein said DPFs are passaged at least once, and 
ekspandiranja izoliranih DPF-ova u jednoslojnoj kulturi bez kolagenske prevlake, pri čemu su navedeni DPF-ovi barem jednom pomaknuti,
A compound according to claim 1 or claim 2 for use in the treatment of cancer, in particular solid tumors, more particularly breast, colon, lung and prostate tumors. 
Spoj prema zahtjevu I ili zahtjevu 2 za uporabu u liječenju raka, posebno solidnih tumora, točnije tumora dojke, kolona, pluća i prostato.
An immunogenic composition comprising S . pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid which is diphtheria toxoid or CRM197 and further comprising conjugates of S . pneumoniae capsular saccharides 1, 4, 5, 6B, 7F, 9V, 14, 18C and 23F, wherein the first bacterial toxoid is a different protein to the second bacterial toxoid. 
Imunogeni pripravak, naznačen time što sadrži konjugate saharida iz kapsule bakterije S. pneumonijae iz serotipova 19A i 19F, gdje je 19A konjugiran s prvim bakterijskim toksoidom, koji je pneumolizin, difterijski toksoid ili CRM197, a 19F je konjugiran s drugim bakterijskim toksoidom, koji je difterijski toksoid ili CRM197, te što dodatno sadrži konjugate saharida 4, 6B, 9V, 14, 18C, 23F, 1, 5 i 7F iz kapsule bakterije S. pneumonijae, gdje je prosječna veličina saharida 19A između 110 i 700 kDa.
The kit of claim 1, wherein the capture antibody is selected from the group consisting of: mouse anti-human FGFR2 monoclonal antibody; mouse anti- human FGFR3 monoclonal antibody; and 
Komplet prema zahtjevu 1, naznačen time što je protutijelo za hvatanje odabrano iz skupine koja se sastoji od: mišjeg anti-humanog FGFR2 monoklonskog protutijela; mišjeg anti- humanog FGFR3 monoklonskog protutijela; i mišjeg anti-humanog fosfo-FGFR4 poliklonskog protutijela.
Furthermore, the flange 44 of the sleeve 20 is introduced into a slot 55 in the operating fork 23. 
Nadalje, prirubnica 44 rukavca 20 se uvodi u utor 55 u radnu vilicu 23.
The composition for use of claim 1, wherein the method comprises administration of the composition via an intravenous, intraarterial, intraperitoneal, intravesicular, subcutaneous, intrathecal, intrapulmonary, intramuscular, intratracheal, intraocular, transdermal, oral, or inhalation route. 
Pripravak za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što se pripravak daje putem intravenoznog, intraarterijskog, intraperitonealnog, intravezikularnog, potkožnog, mtratekalnog, intrapulmonalnog, intramuskularnog, intratrahealnog, intraokularnog, transdermalnog, oralnog ili inhalacijskog puta primjene.